|
Rockwell Medical, Inc. (RMTI:NASDAQ) Analyst Price Target Update - OTC Outlook |
 |
|
Rockwell Medical, Inc. (RMTI:NASDAQ): The mean estimate for the short term price target for Rockwell Medical, Inc. (RMTI:NASDAQ) stands at $16.6 according to 5 Analysts. The higher price target estimate for the stock has been calculated at $26 while the lower price target estimate is at $4.
Rockwell Medical Technologies (NASDAQ:RMTI) has received a short term rating of buy from research analysts at Zacks with a rank of 2. The company has been rated an average of 2.2 by 5 Wall Street Analysts. 3 analysts have added the shares in their list of strong buys. 1 broker firms have advised hold. 1 market experts have rated it as strong sell. Company has received recommendation from many analysts. Equity Analysts at the Brokerage Firm, Bank of America, reinstates their rating on the shares of Rockwell Medical, Inc. (RMTI:NASDAQ). Bank of America has a Neutral rating on the shares. The rating by the firm was issued on July 8, 2015.
Rockwell Medical, Inc. (RMTI:NASDAQ) witnessed a decline in the market cap on Monday as its shares dropped 1.16% or 0.16 points. After the session commenced at $14, the stock reached the higher end at $14.24 while it hit a low of $13.52. With the volume soaring to 630,885 shares, the last trade was called at $13.64. The company has a 52-week high of $18.8999. The company has a market cap of $684 million and there are 50,169,000 shares in outstanding. The 52-week low of the share price is $8.095. The company shares have rallied 25.91% in the past 52 Weeks. On July 17, 2015 The shares registered one year high of $18.9 and one year low was seen on December 15, 2014 at $8.1. The 50-day moving average is $15.8 and the 200 day moving average is recorded at $11.96. S&P 500 has rallied 8.5% during the last 52-weeks. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.
|